Cell culture studies using adipocytes have shown that NNMT overexpression promotes lipid accumulation and insulin resistance, while NNMT knockdown or inhibition increases NAD+ levels, activates SIRT1, enhances mitochondrial respiration, promotes expression of thermogenic genes including UCP1, and drives white adipocyte browning toward a beige phenotype
GLOW keeps both of those and adds GHK-Cu so the rebuilt tissue ends up more organized better collagen, better elastin, and a smoother repair process overall
Confirming the deficiency with a blood test is what makes that trade-off clear
Interestingly, Martinique (also a French overseas territory) did not show particularly high mortality, although ethnicity data are not available for this territory
So why is the FDA spending time on this topic